Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.66 |
| ▸ | RARB | P10826 | 2/20 | 0.66 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483099 | 0.99 | RARB (0.68) | RARARARBRARGMAOBFFAR1 | |
| SCHEMBL3874777 | 0.86 | RARA (0.63) | RARARARBMAOBMCL1MAOA | |
| SCHEMBL7825340 | 0.86 | RARB (0.71) | RARARARBRARGMAOBMCL1 | |
| SCHEMBL13366264 | 0.86 | RARA (0.55) | RARARARBMAOBFFAR1MAOA | |
| SCHEMBL7814595 | 0.82 | RARB (0.66) | RARARARBRARGMCL1 | |
| SCHEMBL7824715 | 0.82 | RARB (0.66) | RARARARBRARGMCL1 | |
| SCHEMBL5191401 | 0.82 | RARA (0.55) | RARARARBMAOBMCL1MAOA | |
| SCHEMBL1583118 | 0.82 | RARB (0.66) | RARARARBRARGMCL1 | |
| SCHEMBL9626748 | 0.82 | RARB (0.66) | RARARARBRARGMCL1 | |
| SCHEMBL7821266 | 0.82 | RARB (0.66) | RARARARBRARGMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1585751-A | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | RARA 670/4885RARB 701/4885RARG 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.